Soft Tissue Sarcoma – Gastrointestinal Stromal Tumors

Regimen Options

Last Updated: 06/03/2024 See Details

	Evolent Pathways	Febrile Neutropenic Risk	Emetogenic Risk	References
Primary/Preoperative; Postoperative Or Unresectable/Metastatic	imatinib	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Demetri GD, et al. N Engl J Med. 2002;347(7):472-80. Verweij J, et al. Lancet. 2004;364(9440):1127-34. Eisenberg BL, et al. J Surg Oncol. 2009;99(1):42-7.
Subsequent Therapy	sunitinib	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. Demetri GD, et al. Lancet. 2006;368(9544):1329-38.
	regorafenib	Low	Low	NCCN Guidelines® for Soft Tissue Sarcoma V.2.2017. George S, et al. J Clin Oncol. 2012;30(19):2401-7. Demetri GD, et al. Lancet. 2013;381(9863):295-302.
	Best Supportive Care or Clinical Trial	NCCN Guidelines® for Supportive Care.

Primary/Preoperative; Postoperative Or Unresectable/Metastatic

Evolent Pathways

imatinib

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Subsequent Therapy

Evolent Pathways

sunitinib

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

regorafenib

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

Best Supportive Care or Clinical Trial

References

Pathways and Low-Value Regimens